공시 • May 14
PHC Holdings Corporation, Annual General Meeting, Jun 24, 2026 PHC Holdings Corporation, Annual General Meeting, Jun 24, 2026. 공시 • Apr 03
PHC Holdings Corporation to Report Fiscal Year 2026 Results on May 13, 2026 PHC Holdings Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 13, 2026 공시 • Jan 02
Phc Holdings Corporation Announces Resignation of Koichiro Sato as Senior Executive Vice President, Representative Director and Chief Operating Officer, Effective January 2, 2026 On December 31, 2025 (the “Execution Date”), Senseonics Holdings Inc. (the “Company”), Senseonics, Incorporated, a wholly-owned subsidiary of the Company (“Senseonics Inc.” and together with the Company, the “Purchaser Parties”) and Ascensia Diabetes Care Holdings AG (the “Seller”) entered into a master asset purchase agreement (the “Master Asset Purchase Agreement”), pursuant to which, among other things, the Purchaser Parties agreed to acquire Seller’s and as applicable, Seller’s affiliates’, right, title and interest in and to certain assets related Seller’s marketing, selling and distribution of the Eversense® product in the United States (such assets, the “U.S. Purchased Assets”). Pursuant to the terms of the Master Asset Purchase Agreement, the Purchaser Parties agreed to assume certain liabilities and obligations associated with the U.S. Purchased Assets (the “U.S. Assumed Liabilities” and together with the U.S. Purchased Assets, the “U.S. Asset Purchase”), including, but not limited to, certain liabilities under the contracts transferred to the Purchaser Parties under the Master Asset Purchase Agreement, liabilities arising out of the use or ownership of the transferred assets after the closing, and liabilities and obligations arising from certain employees whose employment is transferred to Senseonics Inc. pursuant to new employment letter agreements with Senseonics Inc. The U.S. Asset Purchase closed on January 1, 2026 (the “U.S. Closing”). On the Execution Date, in connection with the transactions described in Item 1.01 of this report, Koichiro Sato, Senior Executive Vice President, Representative Director and Chief Operating Officer of PHC Holdings Corporation, the parent company of the Seller, notified the board of directors (the “Board”) of the Company of his resignation from the Board effective immediately. Mr. Sato’s resignation is not due to any disagreements with the Company, management or Board on any matter relating to the Company’s operations, policies, or practices. 공시 • Dec 02
PHC Holdings Corporation to Report Q3, 2026 Results on Feb 12, 2026 PHC Holdings Corporation announced that they will report Q3, 2026 results on Feb 12, 2026 공시 • Sep 04
PHC Holdings Corporation to Report Q2, 2026 Results on Nov 12, 2025 PHC Holdings Corporation announced that they will report Q2, 2026 results on Nov 12, 2025 공시 • May 31
PHC Holdings Corporation to Report Q1, 2026 Results on Aug 07, 2025 PHC Holdings Corporation announced that they will report Q1, 2026 results on Aug 07, 2025 공시 • May 13
PHC Holdings Corporation, Annual General Meeting, Jun 25, 2025 PHC Holdings Corporation, Annual General Meeting, Jun 25, 2025. 공시 • Mar 07
PHC Holdings Corporation to Report Fiscal Year 2025 Results on May 13, 2025 PHC Holdings Corporation announced that they will report fiscal year 2025 results on May 13, 2025 공시 • Dec 06
PHC Holdings Corporation to Report Q3, 2025 Results on Feb 12, 2025 PHC Holdings Corporation announced that they will report Q3, 2025 results on Feb 12, 2025 공시 • Aug 30
Phc Unveils Prototype of Licellgrow, New Cell Expansion System to Support Development of Cell and Gene Therapy Products Manufacturing Process PHC Corporation Biomedical Division will showcase a prototype of its new cell expansion system LiCellGrow at the ISCT (International Society for Cell & Gene Therapy) Europe 2024 Regional Meeting held in Gothenburg, Sweden on September 4-6. LiCellGrow, currently under development, is designed to allow pharmaceutical companies to visualize continuous metabolic changes in cells in real-time and adjust the cell culture automatically to optimize conditions for cell growth. The system seeks to expand availability of cell and gene therapy products by accelerating the manufacturing of specific cells needed for these therapies. CGT, in which a patient’s cells are removed, modified, and reintroduced to the body to fight disease, has emerged as a promising therapeutic field for difficult-to-treat conditions such as cancers and hematologic disorders. Since the patient’s own cells are used as raw materials, it is essential to maintain stable cell quality when producing new cells, to counteract natural variations in cell characteristics and ensure consistency throughout the therapy manufacturing process. The current method of evaluating cell quality by sampling the final product may lower both manufacturing efficiency and yield, increasing production cost. LiCellGrow seeks to enable more efficient and stable manufacture of high-quality CGT products by enabling researchers to monitor and control the cell culture environment in real time, optimizing cell quality while minimizing interruption to the therapy manufacturing process. The system under development uses proprietary In-Line monitoring technology, which continuously measures cell metabolites in the culture medium without the need for repeated sampling by immersing sensors in the medium at all times. LiCellGrow then continuously and accurately measures concentrations of two critical indicators of cell metabolism, glucose and lactate, to offer a visualization of actual changes in the culture environment and cell status. Based on real-time measurement data, the system then automatically exchanges the culture medium to maintain the culture environment in an optimal state. This technology is designed to improve and homogenize cell quality while increasing cell culture efficiency and reducing costs through loss reduction. The system will also feature easy-to-install single-use culture bags with In-Line sensors, enabling closed-system cell culturing to maintain a sterile environment, and can be installed in existing CO2 incubators, enabling researchers to conduct studies using their preferred equipment. LiCellGrow is an example of synergy between the Biomedical Division and IVD Division of PHC Corporation. The In-Line monitoring technology featured in this cell expansion system is newly developed proprietary technology building on the core technology of blood glucose sensor, the main product developed by IVD. By combining this sensor technology from IVD with advanced cell culture environment control technology from the Biomedical Division, PHC seeks to offer researchers and pharmaceutical companies greater value. The Biomedical Division plans to launch LiCellGrow to support the development of manufacturing processes for CGT products globally in the short term, and aims to accelerate development of this system to ultimately support commercialized production of CGT products. LiCellGrow builds on the Biomedical Division’s 20-year history of pioneering solutions in the field of cell therapy, including the Cell Processing Center in 2000 and the Cell Processing Isolator in 2007. Moving forward, they will continue to accelerate the creation of innovative solutions addressing QCD challenges in the therapeutic manufacturing process for early adoption of CGT, aiming to contribute to advancing modalities. 공시 • Jun 28
PHC Holdings Corporation to Report Q1, 2025 Results on Aug 08, 2024 PHC Holdings Corporation announced that they will report Q1, 2025 results on Aug 08, 2024 공시 • May 12
PHC Holdings Corporation, Annual General Meeting, Jun 26, 2024 PHC Holdings Corporation, Annual General Meeting, Jun 26, 2024. 공시 • Mar 09
PHC Holdings Corporation to Report Fiscal Year 2024 Results on May 10, 2024 PHC Holdings Corporation announced that they will report fiscal year 2024 results on May 10, 2024 공시 • Dec 09
PHC Holdings Corporation to Report Q3, 2024 Results on Feb 09, 2024 PHC Holdings Corporation announced that they will report Q3, 2024 results on Feb 09, 2024 공시 • Aug 30
PHC Holdings Corporation to Report Q2, 2024 Results on Nov 10, 2023 PHC Holdings Corporation announced that they will report Q2, 2024 results on Nov 10, 2023 공시 • Jul 11
Bio-Techne Corporation (NasdaqGS:TECH) acquired Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others. Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others on June 22, 2023. The transaction is expected to complete in first quarter of fiscal year 2024. Wenger Plattner acted as legal advisor to Bio-Techne. Bourgeois Avocat SA acted as legal advisor and UBS Investment Bank acted as financial advisor to Lunaphore Technologies.Bio-Techne Corporation (NasdaqGS:TECH) completed the acquisition of Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others on July 10, 2023. 공시 • Jun 23
Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA. Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA on June 22, 2023. The transaction is expected to complete in first quarter of fiscal year 2024. Wenger Plattner acted as legal advisor to Bio-Techne. Bourgeois Avocat SA acted as legal advisor and UBS Investment Bank acted as financial advisor to Lunaphore Technologies. 공시 • Jun 15
PHC Holdings Corporation (TSE:6523) acquired remaining 30% stake in Scimed (Asia) Pte Ltd. PHC Holdings Corporation (TSE:6523) acquired remaining 30% stake in Scimed (Asia) Pte Ltd on June 15, 2023.PHC Holdings Corporation (TSE:6523) completed the acquisition of remaining 30% stake in Scimed (Asia) Pte Ltd on June 15, 2023. 공시 • May 28
PHC Holdings Corporation to Report Q1, 2024 Results on Aug 10, 2023 PHC Holdings Corporation announced that they will report Q1, 2024 results on Aug 10, 2023 공시 • May 13
PHC Holdings Corporation, Annual General Meeting, Jun 23, 2023 PHC Holdings Corporation, Annual General Meeting, Jun 23, 2023.